MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
common stock, warrants...
$28,289K
Redemption of marketable
securities
-$16,500K
Proceeds from atm
offering, net of sales...
$2,502K
Cash received from
the sale of property...
$40K
Net cash provided by
financing activities
$26,291K
Net cash provided by
investing activities
$75K
Canceled cashflow
$4,500K
Canceled cashflow
$16,465K
Net increase
(decrease) in cash, cash...
$4,679K
Canceled cashflow
$21,687K
Repayment of term loans
-$4,500K
Research and development
contract liability,...
$5,250K
Stock-based compensation
$4,744K
Decrease in the carrying
amount of right-of-use...
$2,522K
Accounts payable
$1,125K
Deposits
$1,125K
Depreciation and
amortization
$958K
Other payable
$689K
Accretion of final payment
of term loan
$130K
Amortization of debt issuance
costs
$37K
Loss (gain) on fixed
asset disposal
-$31K
Purchases of marketable
securities
$16,288K
Purchases of property and
equipment
$177K
Net cash used in
operating activities
-$21,687K
Canceled cashflow
$16,611K
Net loss
-$26,602K
Accounts receivable
$4,601K
Operating lease liability
-$2,572K
Foreign withholding tax
receivable
$1,899K
Accrued expenses
-$1,297K
Prepaid expenses and
other current assets
$1,115K
Amortization of
premium/discount on purchased...
-$212K
Back
Back
Cash Flow
source: myfinsight.com
Cue Biopharma, Inc. (CUE)
Cue Biopharma, Inc. (CUE)